학술논문

Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.
Document Type
Article
Source
Clinical & Experimental Immunology. Dec1990, Vol. 82 Issue 3, p559-566. 8p.
Subject
*CYTOMEGALOVIRUS diseases
*HIV infections
*ANTIGENS
*T cells
*SERUM
*AIDS
Language
ISSN
0009-9104
Abstract
In order to delineate the molecular pathogenesis of the increased susceptibility to CMV disease in HIV infection, the patterns of antigen responsiveness in HIV-infected and non-infected individuals were investigated. CMV was fractionated by SDS-PAGE and electroblotted onto nitrocellulose. Lymphoproliferative responses of healthy HIV .CMV individuals and HIV-,CMV+ asymptomatic patients to a whole CMV antigen preparation and to 20 fractions of nitrocellulose-bound CMV were then compared, Three fractions of approximate molecular weight of 130-165,65-75, and 55 65 kD appeared to contain the major T cell stimulating antigens for HIV- , CMV+ individuals. A statistically significant depression of responses lo fractions containing antigens in the ranges of 130-165 kD and 55-65 kD but not to whole CMV was seen in HIV+ individuals compared with controls. In healthy controls, the sum of the proliferative responses as measured by ³H-thymidine uptake to these three major fractions was approximately equal to the response to a whole CMV antigen preparation., whereas it was less than half of this response in five out of six HIV+ subjects. When antibody activities to CMV antigens were analysed by immunoblotting of sera from the two subject groups and also sera of ARC and AIDS patients, a selective loss of reactivity was revealed in 10 outof 19 HIV+ subjects to a band of 26-28k D whereas all 15 HIV- CMV+ controls recognized this band. Serum IgG and IgM values were both significantly higher in HIV+ individuals than in controls. These findings suggest that specific lesions in the repertoire of immune responsiveness to CMV antigens occur in HIV+ individuals. [ABSTRACT FROM AUTHOR]